S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
NASDAQ:TNDM

Tandem Diabetes Care Stock Forecast, Price & News

$127.18
-0.22 (-0.17 %)
(As of 10/22/2021 04:00 PM ET)
Add
Compare
Today's Range
$125.79
$128.50
50-Day Range
$102.15
$134.30
52-Week Range
$76.19
$136.10
Volume358,029 shs
Average Volume696,206 shs
Market Capitalization$8.02 billion
P/E Ratio2,544.11
Dividend YieldN/A
Beta0.28
30 days | 90 days | 365 days | Advanced Chart
Receive TNDM News and Ratings via Email

Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter.


Tandem Diabetes Care logo

About Tandem Diabetes Care

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TNDM
Employees
1,500
Year Founded
2006

Sales & Book Value

Annual Sales
$498.83 million
Book Value
$6.01 per share

Profitability

Net Income
$-34.38 million

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$8.02 billion
Next Earnings Date
11/3/2021 (Confirmed)
Optionable
Optionable

Social Links


MarketRank

Overall MarketRank

2.20 out of 5 stars

Medical Sector

353rd out of 1,359 stocks

Surgical & Medical Instruments Industry

37th out of 124 stocks

Analyst Opinion: 2.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -












Tandem Diabetes Care (NASDAQ:TNDM) Frequently Asked Questions

Is Tandem Diabetes Care a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Tandem Diabetes Care stock.
View analyst ratings for Tandem Diabetes Care
or view top-rated stocks.

What stocks does MarketBeat like better than Tandem Diabetes Care?

Wall Street analysts have given Tandem Diabetes Care a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tandem Diabetes Care wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Tandem Diabetes Care?

Tandem Diabetes Care saw a increase in short interest in September. As of September 30th, there was short interest totaling 4,550,000 shares, an increase of 23.0% from the September 15th total of 3,700,000 shares. Based on an average daily volume of 733,500 shares, the short-interest ratio is presently 6.2 days. Approximately 7.4% of the shares of the company are sold short.
View Tandem Diabetes Care's Short Interest
.

When is Tandem Diabetes Care's next earnings date?

Tandem Diabetes Care is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Tandem Diabetes Care
.

How can I listen to Tandem Diabetes Care's earnings call?

Tandem Diabetes Care will be holding an earnings conference call on Wednesday, November 3rd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Tandem Diabetes Care's earnings last quarter?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) issued its quarterly earnings data on Wednesday, August, 4th. The medical device company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.14. The medical device company earned $172.14 million during the quarter, compared to the consensus estimate of $143.36 million. Tandem Diabetes Care had a net margin of 1.08% and a trailing twelve-month return on equity of 3.68%. The business's revenue for the quarter was up 57.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.45) EPS.
View Tandem Diabetes Care's earnings history
.

How has Tandem Diabetes Care's stock been impacted by COVID-19 (Coronavirus)?

Tandem Diabetes Care's stock was trading at $66.33 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TNDM stock has increased by 91.7% and is now trading at $127.18.
View which stocks have been most impacted by COVID-19
.

When did Tandem Diabetes Care's stock split? How did Tandem Diabetes Care's stock split work?

Tandem Diabetes Care shares reverse split on the morning of Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.

What guidance has Tandem Diabetes Care issued on next quarter's earnings?

Tandem Diabetes Care updated its FY 2021 earnings guidance on Wednesday, September, 1st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $670 million-$685 million, compared to the consensus revenue estimate of $637.16 million.

What price target have analysts set for TNDM?

8 brokerages have issued 1-year price objectives for Tandem Diabetes Care's stock. Their forecasts range from $90.00 to $153.00. On average, they expect Tandem Diabetes Care's stock price to reach $130.13 in the next twelve months. This suggests a possible upside of 2.3% from the stock's current price.
View analysts' price targets for Tandem Diabetes Care
or view top-rated stocks among Wall Street analysts.

Who are Tandem Diabetes Care's key executives?

Tandem Diabetes Care's management team includes the following people:
  • John F. Sheridan, President, Chief Executive Officer & Director
  • James Leal, Senior Vice President-Operations
  • Leigh A. Vosseller, CFO, Treasurer, Principal Accounting Officer & EVP
  • Manuel Jaime, Senior Vice President-Technology & Digital Health
  • Michael Michaud, Vice President-Research & Development

What is John Sheridan's approval rating as Tandem Diabetes Care's CEO?

11 employees have rated Tandem Diabetes Care CEO John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among Tandem Diabetes Care's employees.

What other stocks do shareholders of Tandem Diabetes Care own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Square (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL).

What is Tandem Diabetes Care's stock symbol?

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Who are Tandem Diabetes Care's major shareholders?

Tandem Diabetes Care's stock is owned by a number of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (0.55%), Redwood Investments LLC (0.25%), Frontier Capital Management Co. LLC (0.11%), Assenagon Asset Management S.A. (0.07%), Oregon Public Employees Retirement Fund (0.03%) and Louisiana State Employees Retirement System (0.03%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, Christopher J Twomey, David B Berger, Dick Allen, James Leal, John F Sheridan, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson and Susan Morrison.
View institutional ownership trends for Tandem Diabetes Care
.

Which institutional investors are selling Tandem Diabetes Care stock?

TNDM stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Virginia Retirement Systems ET AL, Frontier Capital Management Co. LLC, WealthTrust Axiom LLC, Level Four Financial LLC, and IFP Advisors Inc. Company insiders that have sold Tandem Diabetes Care company stock in the last year include Brian B Hansen, Christopher J Twomey, David B Berger, James Leal, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson, and Susan Morrison.
View insider buying and selling activity for Tandem Diabetes Care
or view top insider-selling stocks.

Which institutional investors are buying Tandem Diabetes Care stock?

TNDM stock was purchased by a variety of institutional investors in the last quarter, including Redwood Investments LLC, Oregon Public Employees Retirement Fund, Louisiana State Employees Retirement System, Tributary Capital Management LLC, New Mexico Educational Retirement Board, State of Alaska Department of Revenue, Pacer Advisors Inc., and Axiom Investment Management LLC.
View insider buying and selling activity for Tandem Diabetes Care
or or view top insider-buying stocks.

How do I buy shares of Tandem Diabetes Care?

Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tandem Diabetes Care's stock price today?

One share of TNDM stock can currently be purchased for approximately $127.18.

How much money does Tandem Diabetes Care make?

Tandem Diabetes Care has a market capitalization of $8.02 billion and generates $498.83 million in revenue each year. The medical device company earns $-34.38 million in net income (profit) each year or ($0.39) on an earnings per share basis.

How many employees does Tandem Diabetes Care have?

Tandem Diabetes Care employs 1,500 workers across the globe.

When was Tandem Diabetes Care founded?

Tandem Diabetes Care was founded in 2006.

What is Tandem Diabetes Care's official website?

The official website for Tandem Diabetes Care is www.tandemdiabetes.com.

Where are Tandem Diabetes Care's headquarters?

Tandem Diabetes Care is headquartered at 11075 ROSELLE STREET, San Diego CA, 92121.

How can I contact Tandem Diabetes Care?

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at (858) 366-6900 or via email at [email protected].


This page was last updated on 10/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.